Jobs

Business Development Executive - Spin-out


Salary: £50k-70k


Location: London, flexible working requests will be considered


Please note that there is no closing date for this role. Please do not delay your application to avoid disappointment.


The Commercial Partnerships team (CP) is dedicated to the development and commercialisation of innovative research. The team accelerates the translation of new ideas into treatments by bringing together the expertise, capabilities, and resources of CRUK and its academic network with that of industry partners.

Mogrify is a cell therapy development company. We have developed a systematic big data-science approach powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo) for direct cell programming. This allows the conversion of any mature cell type into any other mature cell type without traversing a pluripotent stem cell- or progenitor cell-state. We are applying this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development.

Mogrify is a cell therapy development company. We have developed a systematic big data-science approach powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo). This allows the conversion of any mature cell type into any other mature cell type without traversing a pluripotent stem cell- or progenitor cell-state. We are applying this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development.

Mogrify is a cell therapy development company. We have developed a systematic big data-science approach (Rackham et al., Nature Genetics, 2016) powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo). This allows the conversion of any mature cell type into any other mature cell type without traversing a pluripotent stem cell- or progenitor cell-state.

Mogrify is a cell therapy development company. We have developed a systematic big data-science approach (Rackham et al., Nature Genetics, 2016) powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo). This allows the conversion of any mature cell type into any other mature cell type without traversing a pluripotent stem cell- or progenitor cell-state.

Mogrify is a cell therapy development company whose technology was developed in order to identify the combination of transcription factors required to convert any cell type into any other cell type. We are applying this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development.

Our Client is an acoustic sensing technology company about to be spun out of Imperial College London. The company has a mission to transform the way farming is done with its’ acoustic sensing and monitoring technologies. The company is passionate about innovating the way the agricultural ecosystem is monitored, improving the health of cultivated plants, and empowering farmers to make informed decisions on pest control in a timely and efficient manner.

Pages